68 filings
Page 2 of 4
8-K
6j9fp7 dn
23 Jan 23
Departure of Directors or Certain Officers
7:31am
8-K
bze3qkzt9 sujzx4pbl
8 Nov 22
Bicycle Therapeutics Announces First Patient Dosed in BT8009 Phase II Expansion Cohorts and Provides Program Update
7:07am
8-K
q15isp
3 Nov 22
Bicycle Therapeutics Reports Third Quarter 2022 Financial Results and Provides Corporate Update
7:08am
8-K
cpcyo 4wojb67mwx4o
7 Sep 22
Bicycle Therapeutics Announces BT5528 Phase I Dose Escalation Results in Patients with Advanced Solid Tumors
7:03am
8-K
8n1mop0bpzbfk fj
4 Aug 22
Bicycle Therapeutics Reports Second Quarter 2022 Financial Results and Provides Corporate Update
7:03am
8-K
frfg79
15 Jul 22
Entry into a Material Definitive Agreement
5:22pm
8-K
4lbji989
12 Jul 22
Bicycle Therapeutics Announces Further Expansion of Genentech Immuno-Oncology Collaboration
4:00pm
8-K
g7hxr5aqeh0vhoqf5e
27 Jun 22
Submission of Matters to a Vote of Security Holders
4:10pm
8-K
yk3zwsa5p
5 May 22
Bicycle Therapeutics Reports First Quarter 2022 Financial Results and Provides Corporate Update
7:06am
8-K
v61tw
12 Apr 22
Bicycle Therapeutics Announces Interim BT8009 Phase I Clinical Trial Results at the 2022 AACR Annual Meeting
4:14pm
8-K
ko4v7918u2f cl0
1 Mar 22
Bicycle Therapeutics Reports Fourth Quarter and Full Year 2021 Financial Results and Provides Corporate Update
7:00am
8-K
090cbgfb082bct8m6fy
5 Jan 22
Bicycle Therapeutics Announces Continued Clinical Progress and Updates to Management Team
7:14am
8-K
e9v6c7x2
8 Nov 21
Regulation FD Disclosure
5:02pm
8-K
gpw2hjmsr
4 Nov 21
Bicycle Therapeutics Reports Third Quarter 2021 Financial Results and Provides Corporate Update
7:00am
8-K
x24u tybt5txbffwj
26 Oct 21
Bicycle Therapeutics Announces Expansion of Genentech Immuno-Oncology Collaboration
8:58am
8-K
lsv4rniw0 xfnla
14 Oct 21
Entry into a Material Definitive Agreement
12:00am
8-K
rqrx v86b
7 Oct 21
Bicycle Therapeutics Announces Interim BT5528 Phase I Clinical Trial Results and Preliminary Results from Ongoing BT8009 Phase I Clinical Trial
4:14pm
8-K
82bob504zv9v 7q
5 Aug 21
Bicycle Therapeutics Reports Second Quarter 2021 Financial Results and Provides Corporate Update
7:00am
8-K
0o5yh84fq73
13 Jul 21
Bicycle Therapeutics Enters Exclusive License and Collaboration Agreement with Ionis to Develop Targeted Oligonucleotide Therapeutics
7:54am
8-K
ka0kvpk1k
28 Jun 21
Submission of Matters to a Vote of Security Holders
4:43pm